Extended Release Formulations of Anticonvulsant Medications

Collins, Rebeccah J.; Garnett, William R.

doi:10.2165/00023210-200014030-00003

Cited by 16 publications

(1 citation statement)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Accordingly, these side effects are reported less frequently by patients taking longacting formulations of these drugs than those taking short-acting formulations [47][48][49][50] . For patients with epilepsy, taking consecutive doses of immediate-release antiepileptic drugs (many of which have short half-lives and narrow therapeutic indices 51 ) results in large peak-totrough fluctuations, which may increase the risk of both seizures and concentration-dependent toxicity 52 . Extended-release formulations of antiepileptic drugs such as phenytoin (Dilantin) and valproate (Depakote ER), in comparison, are associated with improved tolerability, offer significant improvements in quality of life and can mitigate the effects of missed or delayed doses 53 based on the type of release.…”

Section: Mitigation Of Concentration-dependent Adverse Effectsmentioning

confidence: 99%

Overcoming barriers to patient adherence: the case for developing innovative drug delivery systems

Baryakova

Pogostin

Langer

et al. 2023

Nat Rev Drug Discov

129

View full text Add to dashboard Cite

Poor medication adherence is a pervasive issue with considerable health and socioeconomic consequences. Although the underlying reasons are generally understood, traditional intervention strategies rooted in patient-centric education and empowerment have proved to be prohibitively complex and/or ineffective. Formulating a pharmaceutical in a drug delivery system (DDS) is a promising alternative that can directly mitigate many common impediments to adherence, including frequent dosing, adverse effects and a delayed onset of action. Existing DDSs have already positively influenced patient acceptability and improved rates of adherence across various disease and intervention types. The next generation of systems have the potential to instate an even more radical paradigm shift by, for example, permitting oral delivery of biomacromolecules, allowing for autonomous dose regulation and enabling several doses to be mimicked with a single administration. Their success, however, is contingent on their ability to address the problems that have made DDSs unsuccessful in the past.

show abstract

Section: Mitigation Of Concentration-dependent Adverse Effectsmentioning

confidence: 99%

Overcoming barriers to patient adherence: the case for developing innovative drug delivery systems

Baryakova

Pogostin

Langer

et al. 2023

Nat Rev Drug Discov

129

View full text Add to dashboard Cite

show abstract

Immediate-release versus controlled-release carbamazepine in the treatment of epilepsy

Powell¹,

Marson²,

Saunders³

2008

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Immediate-release versus controlled-release carbamazepine in the treatment of epilepsy

Powell

Saunders²,

Marson

2010

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

At present, data from trials do not confirm or refute an advantage for CR CBZ over IR CBZ for seizure frequency or adverse events in patients with newly diagnosed epilepsy.For trials involving epilepsy patients already prescribed IR CBZ, no conclusions can be drawn concerning superiority of CR CBZ with respect to seizure frequency.There is a trend for CR CBZ to be associated with fewer adverse events when compared to IR CBZ. A change to CR CBZ may therefore be a worthwhile strategy in patients with acceptable seizure control on IR CBZ but experiencing unacceptable adverse events. The included trials were of small size, poor methodological quality and possessed a high risk of bias, limiting the validity of this conclusion.Randomised controlled trials comparing CR CBZ to IR CBZ and using clinically relevant outcomes are required to inform the choice of CBZ preparation for patients with newly diagnosed epilepsy.

show abstract

Extended Release Formulations of Anticonvulsant Medications

Cited by 16 publications

References 21 publications

Overcoming barriers to patient adherence: the case for developing innovative drug delivery systems

Overcoming barriers to patient adherence: the case for developing innovative drug delivery systems

Immediate-release versus controlled-release carbamazepine in the treatment of epilepsy

Immediate-release versus controlled-release carbamazepine in the treatment of epilepsy

Contact Info

Product

Resources

About